Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
November 2018
-
Press release
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is… -
Press release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-… -
Story Patient Perspectives
The realities of living with premenopausal metastatic breast cancer
Receiving a breast cancer diagnosis is difficult, but these young women faced an especially challenging diagnosis: stage IV metastatic breast cancer.
-
Story Patient Perspectives
The importance of caregivers
Melanoma survivor T.J. Sharpe discusses his personal experience with cancer and the important role caregivers play in a patient’s road to recovery.
October 2018
-
Press release
Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing… -
Press release
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has… -
Press release
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in… -
Story People and Culture
Flexibility at Novartis: Robert Gschwentner and Stefan Lackner
Gschwentner and Lackner discuss the advantages of their job share.
-
Story People and Culture
Flexibility at Novartis: Ana Graf
Graf explains how flexible working has contributed to her success.
-
Press release
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits… -
Story Discovery
On being and becoming a data science company
A conversation with Novartis Chief Digital Officer Bertrand Bodson
-
Press release
Alcon to develop SMART Suite digital health platform for cataract surgery
SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART…